Abstract:Gene expression signatures predictive of chemotherapeutic response have the potential to greatly extend the reach of precision medicine by allowing medical providers to plan treatment regimens on an individual basis for patients with and without actionable mutations. Most published gene signatures are only capable of predicting response for individual drugs, but currently, a majority of chemotherapy regimens utilize combinations of different agents. We propose a unified framework, called the chemogram, that uses predictive gene signatures to rank the relative predicted sensitivity of different drugs for individual tumor samples. Using this approach, providers could efficiently screen against many therapeutics to identify the drugs that would fit best into a patient's treatment plan at any given time. This can be easily reassessed at any point in time if treatment efficacy begins to decline due to therapeutic resistance. To demonstrate the utility of the chemogram, we first extract predictive gene signatures using a previously established method for extracting pan-cancer signatures inspired by convergent evolution. We derived 3 signatures for 3 commonly used cytotoxic drugs (cisplatin, gemcitabine, and 5-fluorouracil). We then used these signatures in our framework to predict and rank sensitivity among the drugs within individual cell lines. To assess the accuracy of our method, we compared the rank order of predicted response to the rank order of observed response (fraction of surviving cells at a standardized dose) against each of the 3 chemotherapies. Across a majority of cancer types, chemogram-generated predictions were consistently more accurate than randomized prediction rankings, as well as prediction rankings made by randomly generated gene signatures. In addition to the chemogram's ability to rank relative sensitivity for any given tumor, this framework is easily scalable for any number of drugs for which a predictive signature exists. We repeated the process described above for 10 drugs and found that the accuracy of the predicted sensitivity rankings was maintained as the number of drugs in the chemogram's screen increased. Our proposed framework demonstrates the ability of transcriptomic signatures to not only predict chemotherapeutic response but correctly assign rankings of drug sensitivity on an individual basis. With further validation, the chemogram could be easily integrated in a clinical setting, as it only requires gene expression data, which is less expensive than an extensive drug screen and can be performed at scale.

Gene Expression Profiles As Biomarkers for the Prediction of Chemotherapy Drug Response in Human Tumour Cells

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Application of expression genomics for predicting treatment response in cancer.

Expression Profiles Can Predict Both General Chemotherapy and Gemcitabine-Specific Responses in Breast Cancer Patients Receiving Neoadjuvant Therapy

Analysis of Chemotherapy Response Programs in Ovarian Cancers by the Next-Generation Sequencing Technologies

Abstract 1671: Characterization of a Gene Signature Predictive of Cancer Patient Survival Prognosis and Chemo-Response

Systematic identification of genomic markers of drug sensitivity in cancer cells

Personalizing chemotherapy drug selection using a novel transcriptomic chemogram

Integrated Analysis of Gene Expression and Tumor Nuclear Image Profiles Associated with Chemotherapy Response in Serous Ovarian Carcinoma

Characterization of Expression-Based Gene Clusters Gives Insights into Variation in Patient Response to Cancer Therapies

Identifying Anti-Cancer Drug Response Related Genes Using an Integrative Analysis of Transcriptomic and Genomic Variations with Cell Line-Based Drug Perturbations.

Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response

Molecular features that predict the response to antimetabolite chemotherapies

Molecular Biomarkers for Predicting Chemotherapy Response in Lung Cancer.

Prediction of Drug Efficacy for Cancer Treatment Based on Comparative Analysis of Chemosensitivity and Gene Expression Data

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/paclitaxel-Based Treatment in Epithelial Ovarian Cancer.

Genome-wide Profiles of Methylation, Micrornas, and Gene Expression in Chemoresistant Breast Cancer

A novel twelve-gene signature to predict neoadjuvant chemotherapy response and prognosis in breast cancer

Proteomic profiling predicts drug response to novel targeted anticancer therapeutics